The World Health Organization’s Technical Advisory Group on COVID-19 Vaccine Composition recommended the use of a monovalent JN.1 lineage COVID-19 vaccine as one approach to address the ongoing SARS-CoV-2 virus evolution, which is expected to lead to circulation of additional JN.1 descendant strains, Novavax stated. Novavax plans to be ready to deliver our JN.1 protein-based non-mRNA COVID-19 vaccine globally this fall. We have been developing and manufacturing this vaccine candidate at risk and are well positioned for the upcoming vaccination season, the company said.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Shah Capital recommends to appoint two new directors to Novavax board
- Novavax (NASDAQ:NVAX) Jumps Amid Activist Investor Push
- Novavax reports data on updated COVID-19 vaccine
- Upcoming Deadline to Share in Novavax, Inc. (NVAX) Class Action Settlement
- Novavax discloses confidential settlement agreement with Fujifilm